Standard

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. / TREAT NL registry and UK-Irish A-STAR Study Groups.

In: JAAD International, Vol. 10, 01.03.2023, p. 14-24.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

TREAT NL registry and UK-Irish A-STAR Study Groups. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD International. 2023 Mar 1;10:14-24. doi: 10.1016/j.jdin.2022.09.006

Author

TREAT NL registry and UK-Irish A-STAR Study Groups. / Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. In: JAAD International. 2023 ; Vol. 10. pp. 14-24.

BibTeX

@article{0fd38e35b596493eb44e8033250d4cb4,
title = "Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types",
abstract = "Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P < .001), more often had follicular eczema (22.1% vs 2.6%; P < .001), higher baseline Eczema Area and Severity Index (EASI) scores (20.1 vs 14.9; P = .009), less allergic contact dermatitis (30.9% vs 47.4%; P = .03), and less previous phototherapy use (39.7% vs 59.0%; P = .008). When comparing DST and LST corrected for covariates including baseline EASI, DST showed greater mean EASI reduction between baseline and 6 months with only dupilumab (16.7 vs 9.7; adjusted P = .032). No differences were found for adverse events for any treatments (P > .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.",
keywords = "atopic dermatitis, atopic eczema, ciclosporin, daily practice, dupilumab, effectiveness, ethnicity, methotrexate, morphology, race, registry, routine clinical care, safety, skin type, systemic treatment",
author = "Bosma, {Angela L.} and Wouter Ouwerkerk and Heidema, {Madeline J.} and David Prieto-Merino and Ardern-Jones, {Michael R.} and Paula Beattie and Brown, {Sara J.} and Ingram, {John R.} and Irvine, {Alan D.} and Graham Ogg and Prakash Patel and Reynolds, {Nick J.} and Hearn, {R. M. Ross} and Mandy Wan and Warren, {Richard B.} and {TREAT NL registry and UK-Irish A-STAR Study Groups} and Woolf, {Richard T.} and Hyseni, {Ari{\"e}nna M.} and Gerbens, {Louise A. A.} and Spuls, {Phyllis I.} and Carsten Flohr and Middelkamp-Hup, {Maritza A.}",
note = "Funding Information: The authors would like to acknowledge Manja Bloem for her support in preparing the data for analysis. NJR is a National Institute for Health and Care Research (NIHR) Senior Investigator and by the NIHR Newcastle Biomedical Research Center. RBW is supported by the Manchester NIHR Biomedical Research Centre . Publisher Copyright: {\textcopyright} 2022 American Academy of Dermatology, Inc.",
year = "2023",
month = mar,
day = "1",
doi = "10.1016/j.jdin.2022.09.006",
language = "English",
volume = "10",
pages = "14--24",
journal = "JAAD International",
issn = "2666-3287",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types

AU - Bosma, Angela L.

AU - Ouwerkerk, Wouter

AU - Heidema, Madeline J.

AU - Prieto-Merino, David

AU - Ardern-Jones, Michael R.

AU - Beattie, Paula

AU - Brown, Sara J.

AU - Ingram, John R.

AU - Irvine, Alan D.

AU - Ogg, Graham

AU - Patel, Prakash

AU - Reynolds, Nick J.

AU - Hearn, R. M. Ross

AU - Wan, Mandy

AU - Warren, Richard B.

AU - TREAT NL registry and UK-Irish A-STAR Study Groups

AU - Woolf, Richard T.

AU - Hyseni, Ariënna M.

AU - Gerbens, Louise A. A.

AU - Spuls, Phyllis I.

AU - Flohr, Carsten

AU - Middelkamp-Hup, Maritza A.

N1 - Funding Information: The authors would like to acknowledge Manja Bloem for her support in preparing the data for analysis. NJR is a National Institute for Health and Care Research (NIHR) Senior Investigator and by the NIHR Newcastle Biomedical Research Center. RBW is supported by the Manchester NIHR Biomedical Research Centre . Publisher Copyright: © 2022 American Academy of Dermatology, Inc.

PY - 2023/3/1

Y1 - 2023/3/1

N2 - Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P < .001), more often had follicular eczema (22.1% vs 2.6%; P < .001), higher baseline Eczema Area and Severity Index (EASI) scores (20.1 vs 14.9; P = .009), less allergic contact dermatitis (30.9% vs 47.4%; P = .03), and less previous phototherapy use (39.7% vs 59.0%; P = .008). When comparing DST and LST corrected for covariates including baseline EASI, DST showed greater mean EASI reduction between baseline and 6 months with only dupilumab (16.7 vs 9.7; adjusted P = .032). No differences were found for adverse events for any treatments (P > .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

AB - Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P < .001), more often had follicular eczema (22.1% vs 2.6%; P < .001), higher baseline Eczema Area and Severity Index (EASI) scores (20.1 vs 14.9; P = .009), less allergic contact dermatitis (30.9% vs 47.4%; P = .03), and less previous phototherapy use (39.7% vs 59.0%; P = .008). When comparing DST and LST corrected for covariates including baseline EASI, DST showed greater mean EASI reduction between baseline and 6 months with only dupilumab (16.7 vs 9.7; adjusted P = .032). No differences were found for adverse events for any treatments (P > .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

KW - atopic dermatitis

KW - atopic eczema

KW - ciclosporin

KW - daily practice

KW - dupilumab

KW - effectiveness

KW - ethnicity

KW - methotrexate

KW - morphology

KW - race

KW - registry

KW - routine clinical care

KW - safety

KW - skin type

KW - systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85141779007&partnerID=8YFLogxK

U2 - 10.1016/j.jdin.2022.09.006

DO - 10.1016/j.jdin.2022.09.006

M3 - Article

C2 - 36387062

VL - 10

SP - 14

EP - 24

JO - JAAD International

JF - JAAD International

SN - 2666-3287

ER -

ID: 27505332